Biotech Digest – IMDZ Reports Data, JNJ Terminates Collaboration

Immune Design announced interim top line data from a Phase 2 clinical trial assessing the combination of its CMB305 and Roche's Tecentriq (atezolizumab) compared to Tecentriq alone in 88 soft tissue sarcoma patients.